Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
about
Chemotherapy for downstaging unresectable liver metastases from colorectal cancerSystematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastasesPreoperative selection of patients with colorectal cancer liver metastasis for hepatic resectionStrategies to increase the resectability of hepatocellular carcinomaSurgical approach for hepatitis C virus-related hepatocellular carcinomaTherapeutic strategies for synchronous and multiple liver metastases from colorectal cancerFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyDesigning liver resections and pushing the envelope with resections for hepatic colorectal metastasescis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsMultisciplinary management of patients with liver metastasis from colorectal cancerUnresolved issues and controversies surrounding the management of colorectal cancer liver metastasisPractice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancerHepatic Lesions that Mimic Metastasis on Radiological Imaging during Chemotherapy for Gastrointestinal Malignancy: Recent Updates.Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasisMultidisciplinary approach of colorectal cancer liver metastases.Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 TNon-alcoholic fatty liver disease: An expanded reviewOpen liver resection for colorectal metastases: better short- and long-term outcomes in patients potentially suitable for laparoscopic liver resectionBody mass index and adverse perioperative outcomes following hepatic resection.The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications.Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure.The surgical treatment of patients with colorectal cancer and liver metastases in the setting of the "liver first" approach.Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome?Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastasesSinusoidal obstruction syndrome (hepatic veno-occlusive disease)Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate.Pathophysiology after pancreaticoduodenectomy.Current state of surgical treatment of liver metastases from colorectal cancerSafety and efficacy of preoperative right portal vein embolization in patients at risk for postoperative liver failure following major right hepatectomy.Pancreatic cancer and FOLFIRINOX: a new era and new questions.Sinusoidal obstruction syndrome (SOS) related to chemotherapy for colorectal liver metastases: factors predictive of severe SOS lesions and protective effect of bevacizumab.Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy.Correlations between histopathological diagnosis of chemotherapy-induced hepatic injury, clinical features, and perioperative morbidityIn vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting.Yttrium-90 Radioembolization of Hepatocellular Carcinoma-Performance, Technical Advances, and Future Concepts.Chemotherapy-associated hepatopathy in korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury.The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.That liver lesion on MDCT in the oncology patient: is it important?A phase III, randomized, controlled, superiority trial evaluating the fibrin pad versus standard of care in controlling parenchymal bleeding during elective hepatic surgery.
P2860
Q24234615-B40E39C5-79B0-4DBD-A708-57C84DF943EDQ26744398-3300E351-3050-42DE-A369-10E38C8E39FCQ26774687-B249FA4D-631A-4647-9C27-1FBC4612C181Q26795530-72C704F9-81B7-4F99-9B96-636D30358A52Q26824046-C26D6158-EBA1-421F-91A3-76D8D93DF110Q26829522-9CB31D99-1DB1-462D-A10B-FE018F123775Q26851060-74C375D2-C668-48B9-95F8-4C4914C3C829Q26864128-B9B968F9-498D-43F5-9E30-AB4FF3BFA658Q27650949-85F9AE0F-3901-4E88-9BB6-7CFD79731A9BQ28069575-504246E9-D21B-48C8-B2A7-3C94B59E8879Q28085651-BEF9368B-8158-4C2E-81DE-85E5F25D44F5Q28252307-4B736B12-E186-4D9E-B1E2-660032C125CEQ33561369-38AA87DC-0469-4C28-83EB-CE5049FDEC43Q33622791-577F39BA-2803-475E-B2D6-B1C00122419AQ33779859-992D32D4-83F7-4E74-B605-5000A03C5B39Q33787851-FDB6614D-DFF9-44A1-B720-5EFE32EC9EFAQ33789868-A46EBC5C-4B1E-41AF-9B11-F8BFF34915D4Q33928163-C9E86132-5D5B-4D18-8913-DEE42C3BDFE8Q34078971-501CDCFC-25FC-4878-93A6-0470483E88CFQ34114133-8A0591D3-F350-4A7E-8FBD-FFE3731E852EQ34225028-EC56FED5-16A6-4C42-A50B-0F7CCB90C82BQ34395932-C3C02581-4025-4B86-9382-2490761C06EAQ34548169-A8B89FCB-6819-4042-9CB5-70A88DE03609Q34601615-2F8C5BE2-DF54-4F9C-8F83-D01C689BC887Q34983459-D33873F8-9014-4D9A-919D-3C51A526C4B3Q35171584-E30BFA97-CDE7-45E4-9847-7F2CD016C69EQ35613910-709FBB94-A4EF-46DD-9094-32ACB64F4912Q35625352-42D7E746-9535-4FBA-8FA6-69594CF5E643Q35653302-84D7E254-987B-46A6-96E9-8BEE95B0CE50Q35657987-AB08A1C3-2493-48AA-870E-C851B228422DQ35755386-0D53649B-0609-45BC-8CDF-515948973758Q35854745-BD539E30-D432-482A-B921-05EE4864B980Q36063262-0443B67B-58BE-4F93-87A6-98052FF31C87Q36063283-863EDEB9-8678-4AA1-A8B5-13A69E1742B9Q36237892-538B1DFB-96A6-41ED-AC7B-D46FFD92549CQ36268905-8591E317-8F48-4B23-AF1D-95026FE55CDFQ36343394-90DC5C05-1DE8-44AE-AB5A-99623B70BD47Q36349575-04924FFE-160D-41FF-8ECD-CF062F78B131Q36361589-A1AF5F0B-005C-4AEA-9273-B778B5D58726Q36498487-0D37F1D7-76BB-4891-B89D-234A8470D5DC
P2860
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@ast
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@en
type
label
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@ast
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@en
prefLabel
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@ast
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@en
P2093
P2860
P356
P1476
Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases.
@en
P2093
P2860
P304
P356
10.1002/BJS.5719
P407
P577
2007-03-01T00:00:00Z